Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.59 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.52 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.44 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21661749 | 0.88 | NAMPT (0.72) | NAMPTCYP17A1CD274LMNAMAPT | |
| SCHEMBL6640528 | 0.85 | NAMPT (0.60) | NAMPTCYP17A1CD274PSMB8HDAC6 | |
| SCHEMBL15451064 | 0.85 | NAMPT (0.54) | NAMPTCYP17A1CD274LMNAMAPT | |
| SCHEMBL23099730 | 0.84 | HDAC3 (0.47) | NAMPTCD274LMNAMAPTKMT2A | |
| SCHEMBL23666325 | 0.84 | STAT3 (0.56) | NAMPTLMNAMAPTKMT2AHDAC6 | |
| SCHEMBL13055402 | 0.84 | CYP17A1 (0.59) | NAMPTCYP17A1PSMB8SMN1; SMN2 | |
| SCHEMBL8770870 | 0.84 | NAMPT (0.67) | NAMPTCYP17A1CD274LMNAKMT2A | |
| SCHEMBL8879852 | 0.84 | NAMPT (0.59) | NAMPTCYP17A1CD274LMNAMAPT | |
| SCHEMBL8773493 | 0.84 | NAMPT (0.67) | NAMPTCYP17A1CD274MAPTKMT2A | |
| SCHEMBL12637634 | 0.83 | CYP17A1 (0.57) | NAMPTCYP17A1CD274PSMB8NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160152579-A1 | OXAZOLIDINONE DERIVATIVES AS PPAR LIGANDS | SERVICIO ANDALUZ DE SALUD (ES) | 2016-06-02 | — | — | US | disclosed |
| EP-3020710-A1 | OXAZOLIDINONE DERIVATIVES AS PPAR LIGANDS | Consejo Superior De Investigaciones Científicas (CSIC) (ES) | 2016-05-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160152579-A1 | OXAZOLIDINONE DERIVATIVES AS PPAR LIGANDS | PPARD, PPARG, PPARA | NAMPT 2643/4885CYP17A1 1286/4885CD274 447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.